Bicara Therapeutics’ (BCAX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report report published on Tuesday,Benzinga reports. They currently have a $30.00 target price on the stock.

A number of other research analysts have also commented on BCAX. Wells Fargo & Company raised their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, BTIG Research initiated coverage on shares of Bicara Therapeutics in a research report on Thursday, January 8th. They set a “buy” rating and a $28.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Trading Down 7.4%

Shares of NASDAQ:BCAX opened at $16.69 on Tuesday. The firm’s 50 day moving average is $17.16 and its two-hundred day moving average is $14.33. The firm has a market capitalization of $914.28 million, a P/E ratio of -7.45 and a beta of -0.79. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). Analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 17,795 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.55, for a total value of $330,097.25. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,696,335.25. The trade was a 10.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Claire Mazumdar sold 41,163 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.86, for a total transaction of $776,334.18. Following the sale, the chief executive officer directly owned 309,892 shares of the company’s stock, valued at approximately $5,844,563.12. This represents a 11.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 90,063 shares of company stock valued at $1,678,012 in the last ninety days. 15.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Larson Financial Group LLC increased its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after buying an additional 4,417 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.